Which of the following vaccines is NOT included in the National Immunization Schedule?
Post-exposure prophylaxis is indicated in?
Which of the following vaccines is classified as a killed vaccine?
In a 10-year-old school child under the school health program, which vaccine should be administered?
In a vaccine trial, relative risk is 0.2. What is the vaccine efficacy?
All of the following statements about MMR vaccine are true EXCEPT:
Adverse reactions following whole-cell pertussis immunization include:
What is the recommended storage temperature for vaccines?
All of the following are recognized adverse effects of DPT vaccine:
Smallpox eradication was not due to:
Explanation: ***Human Papillomavirus (HPV)*** - **HPV vaccine is NOT part of India's routine Universal Immunization Programme (UIP)**, making it the correct answer. - While **pilot programs** have been conducted in some states and various bodies recommend it, HPV has **never been universally included** in India's national immunization schedule. *TT (Tetanus Toxoid)* - **TT is a core component** of India's UIP and is actively used in immunization programs. - Given to **pregnant women** (2 doses during pregnancy) and as **Td vaccine** at 10 and 16 years of age. *OPV (Oral Polio Vaccine)* - While **OPV was phased out** from India's UIP in 2016, it was **historically part** of the national schedule. - India switched to **Injectable Polio Vaccine (IPV)** to eliminate vaccine-derived polio risk, but OPV was previously included. *Measles* - **Measles vaccine is actively included** in India's UIP as part of the **MR (Measles-Rubella) vaccine**. - Administered at **9 months and 16-24 months** of age as part of routine immunization.
Explanation: ***All of the options*** - Post-exposure prophylaxis (PEP) is a critical intervention for various infectious diseases, including **Rabies**, **Diphtheria**, and **HBV**, to prevent disease development after exposure. - The specific PEP regimen varies by disease but generally involves **vaccines**, **immunoglobulins**, or **antiviral medications**. **Rabies PEP:** - Rabies PEP is indicated after potential exposure to a rabid animal and involves a series of **rabies vaccine** doses and, for unvaccinated individuals, **rabies immune globulin (RIG)**. - Rabies is almost always fatal once symptoms appear, making timely PEP crucial. **Diphtheria PEP:** - Diphtheria PEP is recommended for close contacts of individuals with confirmed diphtheria and typically involves administering a **booster dose of diphtheria toxoid vaccine** and sometimes **antibiotics**. - This helps prevent the spread of *Corynebacterium diphtheriae* and disease development in exposed individuals. **HBV PEP:** - HBV PEP is critical after percutaneous or mucosal exposure to **HBV-infected blood** or body fluids. - It usually includes administering **hepatitis B vaccine** and, in some cases, **hepatitis B immune globulin (HBIG)**, depending on the exposed person's vaccination status and the source's HBV status.
Explanation: ***Meningococcal vaccine*** - The meningococcal conjugate and polysaccharide vaccines are **killed vaccines**, containing inactivated bacterial components (polysaccharides) that stimulate an immune response. - They provide protection against *Neisseria meningitidis* and are considered safe for most populations due to their non-live nature. *Varicella* - The varicella vaccine is a **live-attenuated vaccine**, meaning it contains a weakened form of the **varicella-zoster virus**. - This attenuated virus can replicate in the recipient, eliciting a strong and long-lasting immune response, similar to natural infection. *BCG* - The **Bacillus Calmette-Guérin (BCG)** vaccine is a **live-attenuated vaccine** used to prevent tuberculosis. - It contains a weakened strain of **_Mycobacterium bovis_**, which is closely related to *Mycobacterium tuberculosis* but has lost its virulence. *OPV* - The **Oral Polio Vaccine (OPV)** is a **live-attenuated vaccine** that contains weakened but live strains of all three poliovirus serotypes. - It induces strong mucosal immunity in the gut, which is crucial for preventing the wild poliovirus from replicating and spreading.
Explanation: ***Td (Tetanus-Diphtheria)*** - For a 10-year-old child under the school health program in India, the recommended vaccination is a booster dose of **Td (tetanus-diphtheria)**. - This ensures continued **protection against tetanus and diphtheria**, as immunity from the primary series may wane over time. - **Td is preferred over TT** (tetanus toxoid alone) as it provides protection against both tetanus and diphtheria. - This is administered at **10 years and 16 years** as per the Indian Academy of Pediatrics immunization schedule. *DPT* - **DPT (diphtheria, pertussis, tetanus)** is administered in infancy and early childhood (at 6, 10, and 14 weeks, with boosters at 16-24 months and 4-6 years). - The **pertussis component is not given** in later childhood or adolescence due to increased reactogenicity in older children. *BCG* - **BCG (Bacille Calmette-Guérin)** vaccine protects against tuberculosis and is given **at birth** in endemic areas like India. - It is **not routinely administered** to a 10-year-old unless there are specific risk factors or documented non-vaccination status. *MMR* - **MMR (measles, mumps, rubella)** vaccine is given as **two doses**: first at 9-12 months and second at 16-24 months (or 4-6 years). - A 10-year-old child would have **already completed** their MMR vaccination schedule.
Explanation: ***80%*** - Vaccine efficacy is calculated as **(1 - Relative Risk) x 100%**. Given a relative risk of 0.2, the efficacy is (1 - 0.2) x 100% = **80%**. - This value represents the **proportionate reduction** in disease incidence in the vaccinated group compared to an unvaccinated group. *90%* - This would imply a relative risk of 0.1, as **(1 - 0.1) x 100% = 90%**. - The given relative risk of **0.2** does not correspond to 90% efficacy. *95%* - This would imply a relative risk of 0.05, as **(1 - 0.05) x 100% = 95%**. - The given relative risk of **0.2** does not correspond to 95% efficacy. *20%* - This value directly represents the **Relative Risk (RR)** itself, or an efficacy calculated incorrectly as RR x 100%. - Vaccine efficacy is a measure of reduction from the unvaccinated state, hence it is **1 - RR**.
Explanation: ***Correct Answer: All live vaccines without exception are contraindicated in pregnant women*** - This statement is **FALSE**, making it the correct answer to this EXCEPT question - While **most live vaccines are contraindicated in pregnancy** (including MMR), the word **"without exception"** makes this statement incorrect - **Exceptions exist**: Yellow fever vaccine may be administered during pregnancy if travel to endemic areas is unavoidable and the risk of disease outweighs the theoretical vaccine risk - The absolute nature of this statement contradicts clinical guidelines that recognize situational exceptions *True Statement - MMR is a live vaccine* - **MMR vaccine** contains **live-attenuated viruses** of measles, mumps, and rubella - This live-attenuated nature produces robust, long-lasting immunity - Being a live vaccine necessitates contraindications in immunocompromised patients and pregnant women *True Statement - Adverse events from MMR vaccine* - **Fever** typically occurs **6-12 days post-vaccination** (not immediately), reflecting viral replication - **Rash** occurs in approximately **5% of vaccinees** - Other documented adverse events include **arthralgia** (especially in adult women), **aseptic meningitis** (rare), and **lymphadenopathy** - These adverse events are far less severe than complications from natural measles, mumps, or rubella infection *True Statement - Aseptic meningitis and vaccine strains* - **Urabe** and **Leningrad-Zagreb** mumps vaccine strains have been associated with higher rates of vaccine-associated **aseptic meningitis** (approximately 1 in 100,000 to 1 in 1 million doses) - The **Jeryl Lynn strain** (used in the United States and many other countries) has **negligible or no association** with aseptic meningitis - This safety profile makes the Jeryl Lynn strain the preferred mumps component in MMR vaccines
Explanation: ***All of the options*** are well-documented adverse reactions following whole-cell pertussis immunization. *Fever* - **Fever** is a common systemic adverse reaction following whole-cell pertussis immunization, occurring in **10-50%** of recipients - It usually presents within the first **24-48 hours** after vaccination due to the immunostimulatory components of the vaccine - Generally mild and self-limiting, resolving within 1-2 days *Anaphylaxis* - **Anaphylaxis** is a rare but severe allergic reaction that can occur after whole-cell pertussis vaccination (approximately **1 in 1,000,000** doses) - It is an **IgE-mediated type I hypersensitivity reaction** requiring immediate medical intervention with intramuscular epinephrine - Usually occurs within **minutes to hours** after vaccination *Local swelling* - **Local swelling** at the injection site is a very common adverse reaction, occurring in **>50%** of recipients - This reaction is typically mild, localized to the injection site, and represents a normal inflammatory response - Usually resolves spontaneously within **2-3 days** without specific treatment
Explanation: ***+2°C to +8°C*** - This temperature range, often referred to as the **"cold chain,"** is crucial for maintaining the **potency and efficacy** of most vaccines. - Temperatures outside this range can lead to **vaccine degradation**, rendering them ineffective. *-4°C to 0°C* - Temperatures in this range are too cold and could lead to **freezing of vaccines**, especially those with aluminum adjuvants, causing **irreversible damage** to their structure and efficacy. - Frozen vaccines should typically be **discarded** as their potency cannot be guaranteed. *0°C to 4°C* - While close to the recommended range, the lower end of this range **risks freezing**, particularly a concern during temperature fluctuations or with improper refrigeration. - It does not provide the optimal and safe upper buffer for vaccine stability compared to the +2°C to +8°C range. *+4°C to 12°C* - The upper end of this range (above +8°C) is **too warm** and can significantly accelerate the **degradation of heat-sensitive vaccines**, reducing their effectiveness. - Prolonged exposure to temperatures even within the lower part of this range (e.g., constantly at +4°C) might still be suboptimal for long-term storage of some very sensitive vaccines.
Explanation: ***Fever*** - **Fever** is the most common and expected adverse effect after DPT vaccination due to the body's normal immune response to the vaccine components. - It's usually mild and self-limiting, indicating the immune system is building protection. - Occurs in 30-50% of recipients and is considered a typical reaction rather than a complication. *Seizures* - While rare, **seizures** (febrile or afebrile) have been reported as adverse events following DPT vaccination. - Febrile seizures are more common and usually brief without long-term neurological damage. - The risk is very low (approximately 1 in 14,000 doses), and benefits far outweigh this potential risk. *Abscess* - An **abscess** at the injection site can occur as a local complication, though uncommon. - May result from improper injection technique, contamination, or local tissue reaction. - Requires medical attention and possible drainage. *Encephalopathy* - **Encephalopathy** (serious brain injury) was recognized as an extremely rare severe adverse event associated with the **whole-cell pertussis component** of older DPT vaccines. - Risk estimated at less than 1 in 1 million doses. - Modern DTaP (acellular pertussis) vaccines have largely replaced whole-cell DPT to significantly reduce this risk.
Explanation: ***Cross-immunity with animal pox virus*** - While cowpox provided the basis for the smallpox vaccine, **cross-immunity with naturally circulating animal pox viruses** did not contribute to the eradication of smallpox itself. - The eradication was achieved through targeted vaccination campaigns with a **human-specific vaccine**, not by incidental cross-protection from wildlife. *Highly effective vaccine* - The smallpox vaccine was highly effective, providing **strong and long-lasting immunity** against the Variola virus. - This effectiveness was crucial for establishing herd immunity and breaking the chains of transmission. *Subclinical infections do not transmit the disease* - Individuals infected with smallpox either developed **symptomatic disease** or were **immune/resistant** to infection. - The absence of asymptomatic carriers who could silently transmit the virus made it feasible to interrupt transmission through targeted vaccination and surveillance. *Life long immunity* - Both natural infection and successful vaccination provided **long-lasting, often lifelong immunity** to smallpox. - This durable immunity prevented reinfection and helped sustain the protection achieved through vaccination campaigns over time.
Get full access to all questions, explanations, and performance tracking.
Start For Free